Wedbush Maintains an 'Underperform' on The Medicines Company (MDCO); Recent PTO Ruling Lowers Chance of Angiomax Patent Extension
Tweet Send to a Friend
Wedbush maintains an 'Underperform' rating on The Medicines Company (Nasdaq: MDCO), lowers price target from $10 to $9.
Wedbush analyst ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
Wedbush analyst ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
